BACKGROUND: Previous studies suggest that active drug use may compromise HIV treatment among HIV-positive injection drug users (IDU). However, little is known about the differential impacts of cocaine injection, heroin injection, and combined cocaine and heroin injection on plasma HIV-1 RNA suppression. METHODS: Data were derived from a longstanding open prospective cohort of HIV-positive IDU in Vancouver, Canada. Kaplan-Meier methods and Cox proportional hazards regression were used to examine the impacts of different drug use patterns on rates of plasma HIV-1 RNA suppression. RESULTS: Between May 1996 and April 2008, 267 antiretroviral (ART) naïve participants were seen for a median follow-up duration of 50.6 months after initiating ART. The incidence density of HIV-1 RNA suppression was 65.2 (95%CI: 57.0-74.2) per 100 person-years. In Kaplan-Meier analyses, compared to those who abstained from injecting, individuals injecting heroin, cocaine, or combined heroin/cocaine at baseline were significantly less likely to achieve viral suppression (all p<0.01). However, none of the drug use categories remained associated with a reduced rate of viral suppression when considered as time-updated variables (all p>0.05). CONCLUSIONS: Active injecting at the time of ART initiation was associated with lower plasma HIV-1 RNA suppression rates; however, there was no difference in suppression rates when drug use patterns were examined over time. These findings imply that adherence interventions for active injectors should optimally be applied at the time of ART initiation.
BACKGROUND: Previous studies suggest that active drug use may compromise HIV treatment among HIV-positive injection drug users (IDU). However, little is known about the differential impacts of cocaine injection, heroin injection, and combined cocaine and heroin injection on plasma HIV-1 RNA suppression. METHODS: Data were derived from a longstanding open prospective cohort of HIV-positive IDU in Vancouver, Canada. Kaplan-Meier methods and Cox proportional hazards regression were used to examine the impacts of different drug use patterns on rates of plasma HIV-1 RNA suppression. RESULTS: Between May 1996 and April 2008, 267 antiretroviral (ART) naïve participants were seen for a median follow-up duration of 50.6 months after initiating ART. The incidence density of HIV-1 RNA suppression was 65.2 (95%CI: 57.0-74.2) per 100 person-years. In Kaplan-Meier analyses, compared to those who abstained from injecting, individuals injecting heroin, cocaine, or combined heroin/cocaine at baseline were significantly less likely to achieve viral suppression (all p<0.01). However, none of the drug use categories remained associated with a reduced rate of viral suppression when considered as time-updated variables (all p>0.05). CONCLUSIONS: Active injecting at the time of ART initiation was associated with lower plasma HIV-1 RNA suppression rates; however, there was no difference in suppression rates when drug use patterns were examined over time. These findings imply that adherence interventions for active injectors should optimally be applied at the time of ART initiation.
Authors: Julia H Arnsten; Penelope A Demas; Richard W Grant; Marc N Gourevitch; Homayoon Farzadegan; Andrea A Howard; Ellie E Schoenbaum Journal: J Gen Intern Med Date: 2002-05 Impact factor: 5.128
Authors: Evan Wood; Robert S Hogg; Simon Bonner; Thomas Kerr; Kathy Li; Anita Palepu; Silvia Guillemi; Martin T Schechter; Julio S G Montaner Journal: JAMA Date: 2004-09-08 Impact factor: 56.272
Authors: Anita Palepu; Mark Tyndall; Benita Yip; Michael V O'Shaughnessy; Robert S Hogg; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2003-04-15 Impact factor: 3.731
Authors: Andrew R Moss; Judith A Hahn; Sharon Perry; Edwin D Charlebois; David Guzman; Richard A Clark; David R Bangsberg Journal: Clin Infect Dis Date: 2004-09-27 Impact factor: 9.079
Authors: Evan Wood; Julio S G Montaner; Benita Yip; Mark W Tyndall; Martin T Schechter; Michael V O'Shaughnessy; Robert S Hogg Journal: CMAJ Date: 2003-09-30 Impact factor: 8.262
Authors: Evan Wood; Robert S Hogg; Benita Yip; P Richard Harrigan; Michael V O'Shaughnessy; Julio S G Montaner Journal: Ann Intern Med Date: 2003-11-18 Impact factor: 25.391
Authors: Hannah Fraser; Christinah Mukandavire; Natasha K Martin; Matthew Hickman; Myron S Cohen; William C Miller; Peter Vickerman Journal: Int J Epidemiol Date: 2017-04-01 Impact factor: 7.196
Authors: M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy Journal: Drug Alcohol Depend Date: 2016-09-20 Impact factor: 4.492
Authors: N A Mohd Salleh; N Fairbairn; S Nolan; R Barrios; J Shoveller; L Richardson; M-J Milloy Journal: HIV Med Date: 2019-07-29 Impact factor: 3.180
Authors: E Jennifer Edelman; Debbie M Cheng; Evgeny M Krupitsky; Carly Bridden; Emily Quinn; Alexander Y Walley; Dmitry A Lioznov; Elena Blokhina; Edwin Zvartau; Jeffrey H Samet Journal: AIDS Behav Date: 2015-06
Authors: M-J Milloy; Evan Wood; Thomas Kerr; Bob Hogg; Silvia Guillemi; P Richard Harrigan; Julio Montaner Journal: Clin Infect Dis Date: 2015-11-08 Impact factor: 9.079
Authors: Lindsey A Richardson; Thomas H Kerr; Sabina Dobrer; Cathy M Puskas; Silvia A Guillemi; Julio S G Montaner; Evan Wood; M-J S Milloy Journal: AIDS Date: 2015-11-28 Impact factor: 4.177